BCM
EIDX

BlueCrest Capital Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

BlueCrest Capital Management’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,294
Closed -$113K – 1619
2018
Q3 		$113K Buy
11,294
+44
+0.4% +$723 ﹤0.01% 1377
2018
Q2 		$229K Buy
+11,250
New +$236K 0.01% 1247

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlueCrest Capital Management's EIDX Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q4 2018, closing a stake of 11,294 shares — an estimated $113K sold.

BlueCrest Capital Management first reported a position in EIDX in Q2 2018 and held it in 2 quarters. The position peaked at $229K in Q2 2018. 60 funds tracked by Wall St. Rank hold EIDX as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 11,294 Eidos Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $113K.
  • BlueCrest Capital Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's Eidos Therapeutics, Inc. Common Stock position peaked at $229K in Q2 2018.
  • 60 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.